Intranasal inhibitor blocks Omicron and other SARS-CoV-2 variants – Precision vaccinations
The molecule, developed by researchers at the University of Helsinki, can inactivate the SARS-CoV-2 coronavirus peak protein and provide short-term protection against the virus.
Cell cultures and animal studies published by the University of Helsinki on January 10, 2022 show that the new molecule TriSb92, developed by researchers, protects against coronavirus infection for at least eight hours, even when the risk of exposure is high.
The TriSb92 molecule is based on a completely new technical solution. Unlike vaccine protection, the effect of TriSb92 begins immediately after administration.
“In animal models, nasal TriSb92 provided protection against infection in an exposure situation where all unprotected mice were infected,” says the research doctor. Anna Mäkelä, the first author of the study, in a press release.
The nasal product could act as a kind of biological protection against coronary virus infection injected into mucous membranes.
“In other words, we can fairly confidently assume that future variants of SARS-CoV-2 and perhaps even completely new coronaviruses may threaten to cause pandemics, are susceptible to TriSb92,” Mäkelä added.
The findings have been published in a journal that has not yet been evaluated report published 28.12.2021.